Adjuvant Therapy of Breast Cancer – Bisphosphonates

Part of the Cancer Treatment and Research book series (CTAR, volume 151)

The skeleton is a first site of recurrence in every third relapse in breast cancer. Approximately 705 (50–80%) of metastatic breast cancer patients have bone metastases [1]. Bisphosphonates have been used successfully in the treatment of malignant hypercalcaemia and skeletal metastases [2]. The use of bisphosphonates in addition to hormone therapy or chemotherapy reduces the risk of developing skeletal events (new skeletal lesions, progression of existing bone lesions, hypercalcaemia, pathological fractures, palliative radiotherapy or surgery) and the skeletal event rate, as well as increases the time to skeletal event in women with advanced breast cancer and clinically evident bone metastases. Bisphosphonates also reduce bone pain but did not appear to affect survival. During the last 15 years bisphosphonates have been investigated in treatment of primary breast cancer either in prevention of breast cancer recurrences or treatment related bone loss.


Bone Mineral Density Bone Loss Zoledronic Acid Premenopausal Woman Aromatase Inhibitor 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Coleman RE. Skeletal complications of malignancy. Cancer. 1997;80(suppl):1588–94.PubMedCrossRefGoogle Scholar
  2. 2.
    Pavlakis N, Schmidt R, Stockler M. Bisphosphonates for breast cancer. The Chochrane database of systemic reviews. The Chocrane library, Vol 3, 2006.Google Scholar
  3. 3.
    Russell RG, Rogers MJ. Bisphosphonates: From the laboratory to the clinic and back again. Bone 1999;25(1):97–106.PubMedCrossRefGoogle Scholar
  4. 4.
    Hiraga T, Williams PJ, Ueda A, et al. Zoledronic acid inhibits visceral metastases in the 4T1/luc mouse breast cancer model. Clin Cancer Res. 2004;10:4559–67.PubMedCrossRefGoogle Scholar
  5. 5.
    Boissier S, Ferreras M, Peyruchaud O, et al. Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases. Cancer Res. 2000;60:2949–54.PubMedGoogle Scholar
  6. 6.
    Diel I, Solomayer E, Costa SD, et al. Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N Engl J Med. 1998;339:357–63.PubMedCrossRefGoogle Scholar
  7. 7.
    Jaschke A, Baster G, Solomayer E, et al. Adjuvant clodronate treatment improves the overall survival of primary breast cancer patients with micrometastases to bone marrow – a longtime follow-up. ASCO. 2004 (abstract 529), 9a.Google Scholar
  8. 8.
    Saarto T, Blomqvist C, Virkkunen P, et al. Adjuvant clodronate treatment does not reduce the frequency of skeletal metastases in node-positive breast cancer patients: 5-year results of a randomized controlled trial. J Clin Oncol. 2001;19(1):10–17.PubMedGoogle Scholar
  9. 9.
    Saarto T, Blomqvist C, Virkkunen P, et al. Ten-year follow-up of a randomized controlled trial of adjuvant clodronate treatment in node-positive breast cancer patients. Acta Oncol. 2004;43(7)650–6.PubMedCrossRefGoogle Scholar
  10. 10.
    Powles T, Paterson S, Kanis JA, et al. Randomized, placebo-controlled trial of clodronate in patients with primary operable breast cancer. J Clin Oncol. 2002;20(15):3219–24.PubMedCrossRefGoogle Scholar
  11. 11.
    Powles T, Paterson A, McCloskey E, et al. Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer. Br Ca Res Treat. 2006;8:R13.Google Scholar
  12. 12.
    Poole KE, Compston JE. Osteoporosis and its management. BMJ. 2006;333:1251–6.PubMedCrossRefGoogle Scholar
  13. 13.
    Ramaswamy B, Shapiro CL. Osteopenia and osteoporosis in women with breast cancer. Semin Oncol. 2003;30:763–75.PubMedCrossRefGoogle Scholar
  14. 14.
    Chen Z, Maricic M, Bassford TL, et al. Fracture risk among breast cancer survivors: Results from the Women’s Health Initiative Observational Study. Arch Intern Med. 2005;165:552–8.PubMedCrossRefGoogle Scholar
  15. 15.
    Bines J, Oleske DM, Cobleigh MA. Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer. J Clin Oncol. 1996,14:1718–29.PubMedGoogle Scholar
  16. 16.
    Parulekar WR, Day AG, Ottaway JA, et al. Incidence and Prognostic Impact of Amenorrhea During Adjuvant Therapy in High-Risk Premenopausal Breast Cancer: Analysis of a National Cancer Institute of Canada Clinical Trials Group Study-NCIC CTG MA.5 J Clin Oncol. 2005;23(25):6002–8.PubMedCrossRefGoogle Scholar
  17. 17.
    Martin M, Pienkowski T, Mackey J, et al. Adjuvant docetaxel for node-positive breast cancer. New Engl J Med. 2005;352:2302–13.PubMedCrossRefGoogle Scholar
  18. 18.
    Saarto T, Blomqvist C, Välimäki M, et al. Chemical castration induced by adjuvant CMF therapy causes a rapid bone loss which is reduced by clodronate. A randomized study in premenopausal breast cancer women. J Clin Oncol. 1997;15:1341–47.PubMedGoogle Scholar
  19. 19.
    Shapiro CL, Manola J, Leboff M. Ovarian failure after adjuvant chemotherapy is associated with rapid bone loss in women with early-stage breast cancer. J Clin Oncol. 2001;19:3306–11.PubMedGoogle Scholar
  20. 20.
    Pouilles JM, Tremollieres F, Ribot C. The effects of menopause on longitudinal bone loss from the spine. Calcif Tissue Int. 1993;52:340–3.PubMedCrossRefGoogle Scholar
  21. 21.
    Vehmanen L, Saarto T, Elomaa I, et al. Long-term impact of chemotherapy-induced ovarian failure on bone mineral density (BMD) in premenopausal breast cancer patients. The effect of adjuvant clodronate treatment. Eur J Cancer. 2001;37:2373–8.PubMedCrossRefGoogle Scholar
  22. 22.
    El-Hajj Fuleihan G, Salamoun M, Mourad YA, et al. Pamidronate in the prevention of chemotherapyinduced bone loss in premenopausal women with breast cancer. J Clin Endocrinol Metab. 2005;90:3209–14.CrossRefGoogle Scholar
  23. 23.
    Vehmanen L, Saarto T, Blomqvist C, et al. Short-term intermittent intravenous clodronate in the prevention of bone loss related to chemotherapy-induced ovarian failure. Br Ca Res Treat. 2004;87:181–8.CrossRefGoogle Scholar
  24. 24.
    Genant HK, Cann CE, Ettinger B, et al. Quantitative computed tomography of vertebral spongiosa: A sensitive method for detecting early bone loss after oophorectomy. Ann Intern Med. 97:699–705,1982.Google Scholar
  25. 25.
    Fogelman I, Blake GM, Blamey R, et al. Bone mineral density in premenopausal women treated for node-positive early breast cancer with 2 years of goserelin or 6 months of cyclophosphamide, methotrexate and 5-fluorouracil (CMF). Osteoporos Int. 2003;14(12):1001–1006.PubMedCrossRefGoogle Scholar
  26. 26.
    Gnant MF, Mlineritsch B, Luschin-Ebengreuth G, et al. Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: A report from the Austrian Breast and Colorectal Cancer Study Group. J Clin Oncol. 2007;25:826–828.CrossRefGoogle Scholar
  27. 27.
    Love RR, Mazess RB, Barden HS, et al. Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N Engl J Med. 1992;326:852–6.PubMedCrossRefGoogle Scholar
  28. 28.
    Powles TJ, Hickish T, Kanis JA, et al. Effect of tamoxifen on bone mineral density measured by dual-energy X-ray absorptiometry in healthy premenopausal and postmenopausal women. J Clin Oncol. 1996;14:78–84.PubMedGoogle Scholar
  29. 29.
    Vehmanen L, Elomaa I, Blomqvist C, Saarto T. Tamoxifen treatment after adjuvant chemotherapy has opposite effects on bone mineral density in premenopausal patients depending on menstrual status. J Clin Oncol. 2006;24(4):675–80.PubMedCrossRefGoogle Scholar
  30. 30.
    Sverrisdo´ttir A´, Fornander T, Jacobsson H, et al. Bone mineral density among premenopausal women with early breast cancer in a randomized trial of djuvant endocrine therapy. J Clin Oncol. 2004;22:3694–9.CrossRefGoogle Scholar
  31. 31.
    Saarto T, Blomqvist C, Välimäki M, et al. Clodronate improves bone mineral density in postmenopausal breast cancer women treated with adjuvant antiestrogens. Br J Cancer. 1997;75:602–5.PubMedCrossRefGoogle Scholar
  32. 32.
    Powles TJ, McCloskey E, Paterson AH, et al. Oral clodronate and reduction in loss of bone mineral density in women with operable primary breast cancer. J Natl Cancer Inst. 1998;90:704–8PubMedCrossRefGoogle Scholar
  33. 33.
    Howell A, Cuzick J, Maum M, et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet. Jan 1–7, 2005;365(9453):60–2.CrossRefGoogle Scholar
  34. 34.
    Breast International Group (BIG) 1-98 Collaborative Group. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med. 2005;353(26):2747–57.Google Scholar
  35. 35.
    Jakesz R, Jonat W, Gnant M, et al. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: Combined results of ABCSG trial 8 and ARNO 95 trial. Lancet. 2005;366(9484):455–62.PubMedCrossRefGoogle Scholar
  36. 36.
    Boccardo F, Rubagotti A, Puntoni M, et al. Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: Preliminary results of the Italian tamoxifen anastrozole trial. J Clin Oncol. 2005;23:5138–47.PubMedCrossRefGoogle Scholar
  37. 37.
    Coombes RC, Hall E, Gibson LJ, et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med. 2004;350(11):1081–92.PubMedCrossRefGoogle Scholar
  38. 38.
    Goss PE, Ingle JN, Martino S, et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: Updated findings from NCIC CTG MA.17 J Natl Cancer Inst. 2005;97(17):1262–71.PubMedCrossRefGoogle Scholar
  39. 39.
    Coleman RE, et al. Effect of anastrozole on bone mineral density: 5-year results from the ‘Arimidex,’ tamoxifen, alone or in combination (ATAC) trial. Proc Ann Soc Clin Oncol. 2006;24:511a. Abstract.Google Scholar
  40. 40.
    Perez EA, Josse RG, Pritchard KI, et al. Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: A companion study to NCIC CTG MA.17 J Clin Oncol. 2006;24:3629–35PubMedCrossRefGoogle Scholar
  41. 41.
    Coleman RE, Banks LM, Girgis SI, et al. Intergroup Exemestane Study Group. Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): A randomised controlled study. Lancet Oncol. 2007;8:89–91.CrossRefGoogle Scholar
  42. 42.
    Lonning PE, Geisler JK, Lars E, et al. Effects of exemestane administered for 2 years versus placebo on bone mineral density, bone biomarkers, and plasma lipids in patients with surgically resected early breast cancer. J Clin Oncol. 2005;23:5126–37.PubMedCrossRefGoogle Scholar
  43. 43.
    Brufsky A, Harker WG, Beck JT, et al. Zoledronic acid inhibits adjuvant letrozole–induced bone loss in postmenopausal women with early breast cancer. J Clin Oncol. 2007;25:829–36.PubMedCrossRefGoogle Scholar
  44. 44.
    Lester JE, Gutcher SA, Ellis S, et al. The ARIBON study: Reversal of anastrozole (arimidex) induced bone loss with oral monthly ibandronate (bondronate) treatment during adjuvant therapy for breast cancer. Ca Treat Reviews. 2006;32(Suppl 3):121a. Abstract.Google Scholar
  45. 45.
    Saarto T, Vehmanen L, Blomqvist C, et al. 10-year follow-up of the efficacy of clodronate on bone mineral density (BMD) in early stage breast cancer. Proc Ann Soc Clin Oncol. 2006;24:676a. Abstract.Google Scholar
  46. 46.
    Conte PF, Guarneri V. Safety of intravenous and oral bisphosphonates and compliance with dosing regimen. Oncologist. 2004;4 (Suppl 9):28–37.CrossRefGoogle Scholar
  47. 47.
    Woo SB, Hellstein JW, Kalmar JR. Bisphosphonates and osteonecrosis of the jaws. Ann Intern Med. 2006;144:753–61.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2009

Authors and Affiliations

  1. 1.Department of OncologyHelsinki University Central HospitalHelsinkiFinland

Personalised recommendations